GT Biopharma Inc (GTBP)

[TPX]

NEWS! GT Biopharma Announces Presentation of Two Abstracts at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition

LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary NK-engager and Bispecific Antibody Drug Conjugate platforms, announced today that its abstracts have been selected for presentation at the American Society of Hematology (ASH) Annual Meeting being held December 1-4, 2018 in San Diego, CA.

Summarized below are the abstract titles that have been selected for oral and poster presentations. The ASH abstracts are now available online at the conference website, here.

Saturday, December 1, 2018

Session: 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster I
Time: 6:15 PM-8:15 PM PT
Presenter: Upasana Sunil Arvindam, MSc, BSc, Department of Microbiology and Immunology, University of Minnesota, Minneapolis, MN
Abstract #1454: CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia

Monday, December 3, 2018

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, Including HIV and Other Infections: Pre-Clinical T and NK Cell Immunotherapies
Time: 3:15 PM PT
Presenter: Emily Chiu, PhD, Medical School, University of Minnesota, Minneapolis, MN
Abstract #729: Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

https://globenewswire.com/news-release/2018/11/20/1654388/0/en/GT-Biopharma-Announces-Presentation-of-Two-Abstracts-at-the-60th-American-Society-of-Hematology-ASH-Annual-Meeting-Exposition.html